Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.

Abstract:

BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictive relevance in NSCLC patients receiving immune checkpoint inhibitors is unknown. The present research was conducted to investigate the prognostic significance of CD73 expression in NSCLC patients receiving immune checkpoint inhibitors (ICIs). METHODS:We screened 91 patients with advanced or recurrent NSCLC who received immune checkpoint inhibitors. CD73 expression was evaluated immunohistochemically using tissue specimens obtained just before treatment with ICIs. RESULTS:Analysis of progression-free survival (PFS) and overall survival (OS) in relation to several levels of CD73 expression (1%, 10%, 30%, and 50%) showed that both tended to be more favorable as expression of CD73 increased. PFS and OS were longer for patients in whom at least 50% of the tumor cells expressed CD73 than for those in whom <50% of the tumor cells did so. In patients who were positive for EGFR mutation, immune checkpoint inhibitors were significantly more effective in those with high CD73 expression, whereas CD73 expression did not significantly affect the efficacy in patients with EGFR mutation-negative NSCLC. Furthermore, CD73 expression was predictive factor for the PFS independent of PD-L1 expression in patients with EGFR mutation. CONCLUSIONS:High CD73 expression may predict a favorable response to ICIs in NSCLC patients, especially those harboring EGFR mutations. KEY POINTS:Significant findings of the study: In patients who were positive for EGFR mutation, immune checkpoint inhibitors (ICIs) were significantly more effective in those with high CD73 expression, whereas CD73 expression did not significantly affect the efficacy in patients with EGFR mutation-negative NSCLC. WHAT THIS STUDY ADDS:High CD73 expression may predict a favorable response to immune checkpoint inhibitors in NSCLC patients, especially those harboring EGFR mutations.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

doi

10.1111/1759-7714.13346

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

950-955

issue

4

eissn

1759-7706

issn

1759-7714

journal_volume

11

pub_type

杂志文章
  • Histologic transformation of lung cancer during pembrolizumab therapy: A case report.

    abstract::Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13312

    authors: Si X,You Y,Zhang X,Wang H,Wang M,Zhang L

    更新日期:2020-03-01 00:00:00

  • Soluble fms-like tyrosine kinase-1-enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration.

    abstract:BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13175

    authors: Hao D,Li Y,Zhao G,Zhang M

    更新日期:2019-10-01 00:00:00

  • Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma.

    abstract:BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13260

    authors: Lo H,Abel S,Finley G,Weksler B,Colonias A,Wegner RE

    更新日期:2020-02-01 00:00:00

  • A case of huge esophageal carcinosarcoma.

    abstract::Carcinosarcoma of the esophagus is a rare malignant neoplasm with both epithelial and mesenchymal (sarcomatous) components. We describe a case of a 72-year-old man with a huge esophageal tumor which could often have been considered inoperable. However, the patient underwent a curative resection and had a good prognosi...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00069.x

    authors: Hu M,Zhi XY,Sun KL

    更新日期:2011-11-01 00:00:00

  • Analysis of the associated factors for severe weight loss after minimally invasive McKeown esophagectomy.

    abstract:BACKGROUND:This study investigated the risk factors for severe weight loss (SWL) within one year after minimally invasive McKeown esophagectomy. METHODS:Esophageal cancer patients who underwent McKeown esophagectomy between January and July 2017 were prospectively enrolled. Preoperative body weight (PBW) was chosen as...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12934

    authors: Wang P,Li Y,Sun H,Zhang R,Liu X,Liu S,Wang Z,Zheng Y,Yu Y,Chen X,Li H,Zhang J,Liu Q

    更新日期:2019-02-01 00:00:00

  • Safety of endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention.

    abstract:BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12846

    authors: Gil HI,Choe J,Jeong BH,Um SW,Jeon K,Hahn JY,Kim H,Kwon OJ,Chang YS,Lee K

    更新日期:2018-11-01 00:00:00

  • Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.

    abstract:BACKGROUND:Lung cancer is the leading cause of cancer-related deaths. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations, some patients experience little or no response. The Glasgow prognostic score (GPS...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13526

    authors: Kasahara N,Imai H,Naruse I,Tsukagoshi Y,Kotake M,Sunaga N,Kaira K,Maeno T,Asao T,Hisada T

    更新日期:2020-08-01 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13568

    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • The 12th National Lung Cancer Academic Conference in China.

    abstract:BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00125.x

    authors: Liu Y,Chen G,Qiu X,Chen J,Zhou Q

    更新日期:2012-08-01 00:00:00

  • Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases.

    abstract:BACKGROUND:We performed a retrospective analysis to compare the efficacy of whole brain radiotherapy (WBRT) combined with temozolomide (TMZ) versus WBRT alone as first-line treatment for brain metastases (BM). METHODS:Seventy-eight non-small cell lung cancer patients with BM were observed, including 45 patients who re...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12795

    authors: Zhu Y,Fu L,Jing W,Guo D,Kong L,Yu J

    更新日期:2018-09-01 00:00:00

  • MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

    abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13326

    authors: Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

    更新日期:2020-03-01 00:00:00

  • Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

    abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12557

    authors: Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

    更新日期:2018-01-01 00:00:00

  • A nurse-driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery.

    abstract::Enhanced recovery after surgery (ERAS) is a multiprofessional, multidisciplinary and evidence-based program that aims to reduce complications, improve overall prognosis, shorten hospital stays, and promote fast recovery following major surgery. Nurses play a crucial role in the successful implementation of the ERAS pr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13372

    authors: Li Y,Yan C,Li J,Wang Q,Zhang J,Qiang W,Qi D

    更新日期:2020-04-01 00:00:00

  • MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2.

    abstract:BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12442

    authors: Zhao D,Han W,Liu X,Cui D,Chen Y

    更新日期:2017-07-01 00:00:00

  • Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis.

    abstract:BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13622

    authors: Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

    更新日期:2020-10-01 00:00:00

  • Chinese expert consensus on diagnosis and management of acquired respiratory-digestive tract fistulas.

    abstract::Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12856

    authors: Wang H,Ke M,Li W,Wang Z,Li H,Cong M,Zeng Y,Chen L,Lai G,Xie B,Zhang N,Li W,Zhou H,Wang X,Lin D,Zhou Y,Zhang H,Li D,Song X,Wang J,Wu S,Tao M,Sha Z,Tan Q,Han X,Luo L,Ma H,Wang Z

    更新日期:2018-11-01 00:00:00

  • Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature.

    abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00086.x

    authors: Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

    更新日期:2012-02-01 00:00:00

  • Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

    abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13360

    authors: Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

    更新日期:2020-04-01 00:00:00

  • FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.

    abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12504

    authors: Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

    更新日期:2017-11-01 00:00:00

  • Female breast cancer incidence and mortality in China, 2013.

    abstract:BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12426

    authors: Zuo TT,Zheng RS,Zeng HM,Zhang SW,Chen WQ

    更新日期:2017-05-01 00:00:00

  • Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β-catenin signaling pathway.

    abstract:BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12893

    authors: Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

    更新日期:2019-01-01 00:00:00

  • Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.

    abstract::Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12484

    authors: Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

    更新日期:2017-11-01 00:00:00

  • Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

    abstract:BACKGROUND:Nm23-H1 gene has been found to be an inhibitor of tumor metastasis in lung cancer. MicroRNAs (miRNAs) play key roles in tumor metastasis through multiple signaling pathways. This study explored whether the nm23-H1 gene could inhibit invasion and metastasis of lung cancer cells by regulating miRNA-660-5p targ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13308

    authors: Ai C,Ma G,Deng Y,Zheng Q,Gen Y,Li W,Li Y,Zu L,Zhou Q

    更新日期:2020-03-01 00:00:00

  • Self-reported depression among patients with non-small cell lung cancer.

    abstract:BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12179

    authors: Shi Y,Gu F,Hou LL,Hu YQ

    更新日期:2015-05-01 00:00:00

  • Three-dimensional (3D)-printed titanium sternum replacement: A case report.

    abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13655

    authors: Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

    更新日期:2020-11-01 00:00:00

  • Pleomorphic adenoma presenting with a mediastinal mass.

    abstract::Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12013

    authors: Lee YK,Kim YH,Kim GY,Youn HC

    更新日期:2014-01-01 00:00:00

  • Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

    abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13215

    authors: Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

    更新日期:2019-12-01 00:00:00

  • miR-874 directly targets AQP3 to inhibit cell proliferation, mobility and EMT in non-small cell lung cancer.

    abstract:BACKGROUND:Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and high mortality. miR-874 has been determined to play a role in tumor suppression in several cancers. The purpose of our study was to detect the biological mechanisms of miR-874 and AQP3 in NSCLC. METHODS:CCK-8 and Trans...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13428

    authors: Wang S,Wu Y,Yang S,Liu X,Lu Y,Liu F,Li G,Tian G

    更新日期:2020-06-01 00:00:00

  • Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.

    abstract:BACKGROUND:The combination of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is thought to increase treatment efficacy in non-small-cell lung cancer (NSCLC). This study investigated the efficacy and potential mechanisms of different combined modes of icotinib plus pemetrexed in EGFR-mutant lung adenocarcinoma ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12818

    authors: Cui J,Zhang Y,Su D,Li T,Li Y

    更新日期:2018-09-01 00:00:00